Antagonism of estrogen-mediated cell proliferation by raloxifene in prevention of ageing-related prostatic hyperplasia. - Wikidata - awgldk - TriplyDB

Antagonism of estrogen-mediated cell proliferation by raloxifene in prevention of ageing-related prostatic hyperplasia.

Antagonism of estrogen-mediated cell proliferation by raloxifene in prevention of ageing-related prostatic hyperplasia.

http://www.wikidata.org/entity/Q37084590

about

Androgens and estrogens in benign prostatic hyperplasia: past, present and future.Distinct function of estrogen receptor α in smooth muscle and fibroblast cells in prostate development.Selective estrogen receptor modulators for BPH: new factors on the ground.Profile of cell proliferation and apoptosis activated by the intrinsic and extrinsic pathways in the prostate of aging rats.Epithelial-to-mesenchymal transition and estrogen receptor α mediated epithelial dedifferentiation mark the development of benign prostatic hyperplasia.Estradiol promotes epithelial-to-mesenchymal transition in human benign prostatic epithelial cells.[Etiology and pathophysiology of benign prostate hyperplasia].

P2860

Q35231660-49F8B431-A4A8-4B51-B6A8-0A3616DC0E0A Q36533414-9CD74461-B0B7-48B0-94CC-2D5B731660FB Q38115066-D7D324C8-5983-4F93-BED6-17F2570BBF65 Q38704390-9CD1996C-3AFA-4D43-9C3F-236CC5DDCC0E Q42457796-FF03CCC1-95BC-4F5F-8BEF-F80F229F6D58 Q42514114-21401892-0582-40B9-B8B1-F00F0BEF5A1C Q43821228-E8CD34AD-79BB-41D8-94DD-DB9C3A0C2746

P2860

Antagonism of estrogen-mediated cell proliferation by raloxifene in prevention of ageing-related prostatic hyperplasia.

http://www.wikidata.org/entity/Q37084590

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 17 May 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Antagonism of estrogen-mediate ...... related prostatic hyperplasia.

@en

Antagonism of estrogen-mediate ...... related prostatic hyperplasia.

@nl

type

label

Antagonism of estrogen-mediate ...... related prostatic hyperplasia.

@en

Antagonism of estrogen-mediate ...... related prostatic hyperplasia.

@nl

prefLabel

Antagonism of estrogen-mediate ...... related prostatic hyperplasia.

@en

Antagonism of estrogen-mediate ...... related prostatic hyperplasia.

@nl

P1433

Q37084590-97C6C38D-8FE3-4330-B945-28393973C954

P1476

Q37084590-0F343745-EF1C-4D87-A958-3089AFB2336A

P2093

Q37084590-0AD37590-076B-4708-9C10-433E5F2F751D

Q37084590-42B17C07-B2C9-4EE3-BD5C-FFE7F9A8C113

Q37084590-4637AC74-FC49-4817-89EB-D519FAD796F9

Q37084590-6E5F1E73-798E-4591-AC4A-0B9E0A67E82C

Q37084590-7F004698-DF28-4C06-8AF9-FC6FE5E14D2E

Q37084590-A73170D6-D0EF-4A60-A9B6-AD02AC918F98

Q37084590-B9DFC5A1-A6E2-4B7D-896A-D8F5CF8EE5F9

Q37084590-BE3A00D0-53DA-482B-A037-6D35507D7CB9

Q37084590-C8E4EA58-544C-4316-8F3E-1EB5A9853130

Q37084590-D21F97F2-3F8C-4148-8C64-1BE8CDD1E3F3

P2860

Q37084590-0255E9CC-AD91-4EC0-9DD3-F31C0D551BA7

Q37084590-0600CEF3-D99C-497C-8B94-62A4E8BB54A1

Q37084590-0A7509E1-ABC5-438D-B805-2F8BED78AD86

Q37084590-0AF50A79-78D2-4199-8A06-3218237246FF

Q37084590-0B933B20-2ED5-47B5-BFC2-E275A57C528D

Q37084590-0C49B37F-75AA-4DD8-A725-60CD99A9D4AB

Q37084590-23C3C42B-7EBF-4F98-95ED-B29223C540D5

Q37084590-28EC5973-00F0-495B-87B9-77C3E0B702C3

Q37084590-54142598-EF9E-4E79-A1CA-778D690A2DB2

Q37084590-5D5A7AC2-62A3-4894-8C1E-E6255CB327C5

P304

Q37084590-61351233-035C-4D5A-A8F2-85121B543396

P31

Q37084590-B46BCE2E-9B5C-437F-B5C0-5A2A63BF0AB4

P356

Q37084590-66088CFA-8E97-4FEC-8221-5ABDFEBEF7DE

P433

Q37084590-E9EB4E0F-D905-448B-9E79-7BFA2ACC6CD4

P478

Q37084590-F69F932C-D963-480C-94F2-4A5542DD69FA

P577

Q37084590-531C596A-C29E-4F41-A72C-1E8C0388B22B

P698

Q37084590-24B3C9DA-F981-42FE-9A36-7BD64D4EF8F2

P932

Q37084590-FB399C3A-AAA0-41E1-BF85-18ECE0ACA59B

P356

P1433

Asian Journal of Andrology

P1476

Antagonism of estrogen-mediate ...... related prostatic hyperplasia.

@en

P2093

Hong-Shun Ma

http://www.w3.org/2001/XMLSchema#string

Jian-Dang Shi

http://www.w3.org/2001/XMLSchema#string

Ju Zhang

http://www.w3.org/2001/XMLSchema#string

Lin-Feng Chen

http://www.w3.org/2001/XMLSchema#string

Rui Yang

http://www.w3.org/2001/XMLSchema#string

Xiao-Ling Du

http://www.w3.org/2001/XMLSchema#string

Yan Zhu

http://www.w3.org/2001/XMLSchema#string

Ying Zhou

http://www.w3.org/2001/XMLSchema#string

Yu-Xia Ma

http://www.w3.org/2001/XMLSchema#string

Zhan-Po Yang

http://www.w3.org/2001/XMLSchema#string

P2860

Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial

Increased prostate cell proliferation and loss of cell differentiation in mice lacking prostate epithelial androgen receptor

Estrogen in the etiopathogenesis of BPH.

Selective estrogen-receptor modulators -- mechanisms of action and application to clinical practice.

Androgen and prostatic stroma.

Estrogen receptor expression in prostate cancer and premalignant prostatic lesions.

The role of estrogens and estrogen receptors in normal prostate growth and disease.

Pathology of benign prostatic hyperplasia. Insight into etiology.

Proliferation and phenotypic changes of stromal cells in response to varying estrogen/androgen levels in castrated rats.

Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women.

P304

735-743

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/AJA.2010.24

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

2010-05-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20473319

http://www.w3.org/2001/XMLSchema#string

P932

3739309

http://www.w3.org/2001/XMLSchema#string